Cargando…
Medical and social costs after using financial incentives to improve medication adherence: results of a 1 year randomised controlled trial
OBJECTIVE: Offering a financial incentive (‘Money for Medication’) is effective in improving adherence to treatment with depot antipsychotic medications. We investigated the cost-effectiveness in terms of medical costs and judicial expenses of using financial incentives to improve adherence. The eff...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131864/ https://www.ncbi.nlm.nih.gov/pubmed/30201054 http://dx.doi.org/10.1186/s13104-018-3747-1 |
_version_ | 1783354212133896192 |
---|---|
author | Noordraven, Ernst L. Wierdsma, André I. Blanken, Peter Bloemendaal, Anthony F. T. Mulder, Cornelis L. |
author_facet | Noordraven, Ernst L. Wierdsma, André I. Blanken, Peter Bloemendaal, Anthony F. T. Mulder, Cornelis L. |
author_sort | Noordraven, Ernst L. |
collection | PubMed |
description | OBJECTIVE: Offering a financial incentive (‘Money for Medication’) is effective in improving adherence to treatment with depot antipsychotic medications. We investigated the cost-effectiveness in terms of medical costs and judicial expenses of using financial incentives to improve adherence. The effects of financial incentives on depot medication adherence were evaluated in a randomised controlled trial. Patients in the intervention group received €30 a month over 12 months if antipsychotic depot medication was accepted. The control group received mental health care as usual. For 133 patients outcomes were calculated based on self-reported service use and delinquent behaviour and expressed as standard unit costs to value resource use. RESULTS: The financial incentive resulted in higher average costs related to mental health care (€449.6 versus €355.7). and lower medical costs related to other healthcare services (€52.0 versus €78.4). Relevant differences in social costs related to delinquent behaviour were not found. Although wide confidence intervals indicate uncertainty, incremental cost-effectiveness ratio’s (ICER) indicate that it costs €2080 for achieving a 20% increase in adherence or €3332 for achieving over 80% adherence. In sum, offering money as financial incentive for increasing compliance did not lead to an overall cost reduction as compared to care as usual. Trial registration NTR2350, 01 June 2010 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13104-018-3747-1) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6131864 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-61318642018-09-13 Medical and social costs after using financial incentives to improve medication adherence: results of a 1 year randomised controlled trial Noordraven, Ernst L. Wierdsma, André I. Blanken, Peter Bloemendaal, Anthony F. T. Mulder, Cornelis L. BMC Res Notes Research Note OBJECTIVE: Offering a financial incentive (‘Money for Medication’) is effective in improving adherence to treatment with depot antipsychotic medications. We investigated the cost-effectiveness in terms of medical costs and judicial expenses of using financial incentives to improve adherence. The effects of financial incentives on depot medication adherence were evaluated in a randomised controlled trial. Patients in the intervention group received €30 a month over 12 months if antipsychotic depot medication was accepted. The control group received mental health care as usual. For 133 patients outcomes were calculated based on self-reported service use and delinquent behaviour and expressed as standard unit costs to value resource use. RESULTS: The financial incentive resulted in higher average costs related to mental health care (€449.6 versus €355.7). and lower medical costs related to other healthcare services (€52.0 versus €78.4). Relevant differences in social costs related to delinquent behaviour were not found. Although wide confidence intervals indicate uncertainty, incremental cost-effectiveness ratio’s (ICER) indicate that it costs €2080 for achieving a 20% increase in adherence or €3332 for achieving over 80% adherence. In sum, offering money as financial incentive for increasing compliance did not lead to an overall cost reduction as compared to care as usual. Trial registration NTR2350, 01 June 2010 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13104-018-3747-1) contains supplementary material, which is available to authorized users. BioMed Central 2018-09-10 /pmc/articles/PMC6131864/ /pubmed/30201054 http://dx.doi.org/10.1186/s13104-018-3747-1 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Note Noordraven, Ernst L. Wierdsma, André I. Blanken, Peter Bloemendaal, Anthony F. T. Mulder, Cornelis L. Medical and social costs after using financial incentives to improve medication adherence: results of a 1 year randomised controlled trial |
title | Medical and social costs after using financial incentives to improve medication adherence: results of a 1 year randomised controlled trial |
title_full | Medical and social costs after using financial incentives to improve medication adherence: results of a 1 year randomised controlled trial |
title_fullStr | Medical and social costs after using financial incentives to improve medication adherence: results of a 1 year randomised controlled trial |
title_full_unstemmed | Medical and social costs after using financial incentives to improve medication adherence: results of a 1 year randomised controlled trial |
title_short | Medical and social costs after using financial incentives to improve medication adherence: results of a 1 year randomised controlled trial |
title_sort | medical and social costs after using financial incentives to improve medication adherence: results of a 1 year randomised controlled trial |
topic | Research Note |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131864/ https://www.ncbi.nlm.nih.gov/pubmed/30201054 http://dx.doi.org/10.1186/s13104-018-3747-1 |
work_keys_str_mv | AT noordravenernstl medicalandsocialcostsafterusingfinancialincentivestoimprovemedicationadherenceresultsofa1yearrandomisedcontrolledtrial AT wierdsmaandrei medicalandsocialcostsafterusingfinancialincentivestoimprovemedicationadherenceresultsofa1yearrandomisedcontrolledtrial AT blankenpeter medicalandsocialcostsafterusingfinancialincentivestoimprovemedicationadherenceresultsofa1yearrandomisedcontrolledtrial AT bloemendaalanthonyft medicalandsocialcostsafterusingfinancialincentivestoimprovemedicationadherenceresultsofa1yearrandomisedcontrolledtrial AT muldercornelisl medicalandsocialcostsafterusingfinancialincentivestoimprovemedicationadherenceresultsofa1yearrandomisedcontrolledtrial |